HOME ·

09926.HK

AKESO (09926.HK): Phase III Results for Ivonescimab in First-Line Biliary Tract Cancer at ESMO
Tags：
NewTimeSpaceAKESO09926.HK
2026-10-26
AKESO (09926.HK): Completes 20m-share placing, nets HK$1.94bn
Tags：
AKESO09926.HKShare Placing
2026-10-16
AKESO (09926.HK): HARMONi-2 interim analysis of ivonescimab meets key secondary OS endpoint with statistical significance and clinical benefit
Tags：
AKESO09926.HKR&D Progress
2026-09-03
Akesobio (09926.HK): Phase III Trial of Ivonescimab Combined with Chemotherapy Achieves Statistically Significant Positive OS Results
Tags：
Akesobio09926.HK
2026-08-26
AKESO (09926.HK): NMPA Approves Third Indication of Ivonescimab (PD-1/VEGF) for First-Line Treatment of Advanced Squamous NSCLC
Tags：
AKESO09926.HKR&D Progress
2026-08-13
Akeso(09926.HK): Grant of Share Options and Restricted Share Units
Tags：
AKESO09926.HK
2026-07-27
AKESO(09926.HK): Qiyoukang® (Gumokimab) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis
Tags：
AKESO09926.HKNew Drug Application
2026-06-12